IOVA News and Press, Iovance Biotherapeutics Inc. From 07/10/23

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in Post-Anti-PD-1 NSCLC Demonstrated a 26.1% Objective Response Rate (ORR) in Registrational IOV-LUN-...

SAN CARLOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host an investor conference c...

SAN CARLOS, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that the first patient w...

SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the Jefferies Global Healthcare Conference: ...

2023-05-31 08:00:00 ET Summary Iovance is a cell therapy pioneer with a shot at a first ever approval for this drug class in a solid tumor cancer. Data from Iovance's pivotal study looks relatively strong and the FDA has finally accepted the company's BLA after pushing for more da...

2023-05-30 16:18:59 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had approved its biologics license application (BLA) for lifileucel...

2023-05-30 12:08:19 ET After sharp post-market gains in the previous session, Iovance Biotherapeutics ( NASDAQ: IOVA ) continued to trade higher Tuesday as Wall Street reacted to FDA’s decision to grant priority review for the company’s melanoma candidate lifileucel....

2023-05-30 08:34:33 ET Arlington Asset Investment  ( AAIC ) +53% Announce Definitive Merger Agreement. Equitrans Midstream  ( ETRN ) +33% . HeartBeam ( BEAT ) +28% Enters into Strategic Alliance Agreement with Samsung. Wearable Devices  (...

2023-05-26 18:25:32 ET The US FDA has accepted Iovance Biotherapeutics' ( NASDAQ: IOVA ) Biologics License Application for lifileucel for advanced melanoma, sending shares up ~15% in after-hours trading Friday. The candidate has an FDA action date of Nov. 25 as it was...

Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- Iovance Biot...